US FDA’s Bipartisan Support May Offer Shelter From Political Winds, Former Chief Says
Executive Summary
In the wake of 21st Century Cures legislation, next commissioner will have strong support across party lines to undertake smarter regulation aimed at improving the efficiency of the drug development process, former FDA head McClellan says.
You may also be interested in...
Gottlieb Nomination As US FDA Chief Could Signal Changes To Generic Approval Process
Former deputy commissioner will also likely push increased use of biomarkers and more flexibility in off-label communication, among other reforms.
Gottlieb Nomination As US FDA Chief Could Signal Changes To Generic Approval Process
Former deputy commissioner will also likely push increased use of biomarkers and more flexibility in off-label communication, among other reforms.
Trump Slams FDA Regulations In Joint Session Of Congress
US president hit on his sentiments of faster drug approval times and deregulation, signaling FDA could be in for period of sustained criticism.